This mechanism of resistance has been addressed by the introduction of non-covalent BTK inhibitors, among which pirtobrutinib is, to date, the only one approved for the treatment of CLL patients who have relapsed on standard BTK inhibitor therapy. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.